Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
SHR-1702 by Jiangsu Hengrui Medicine for Refractory Acute Myeloid Leukemia: Likelihood of Approval
SHR-1702 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Refractory Acute Myeloid Leukemia. According...
SHR-1702 by Jiangsu Hengrui Medicine for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
SHR-1702 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Relapsed Acute Myeloid Leukemia. According...
SHR-1702 by Jiangsu Hengrui Medicine for Myelodysplastic Syndrome: Likelihood of Approval
SHR-1702 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Myelodysplastic Syndrome. According to GlobalData,...